Sensitivity and precision of activated partial thromboplastin time (APTT) methods. A multicenter study.

Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.

Activated partial thromboplastin time and minor coagulopathies.

An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant.

Activated partial thromboplastin time measurements in citrated canine plasma.

Sensitivity of the thrombin clotting time and activated partial thromboplastin time to low level of antithrombin III during heparin therapy.

The partial thromboplastin time.

The influence of time, temperature and packed cell on activated partial thromboplastin time and prothrombin time.

Prothrombin Time and Activated Partial Thromboplastin Time Testing: A Comparative Effectiveness Study in a Million-Patient Sample.

An analysis of duplicate testing of prothrombin time and activated partial thromboplastin time assays.

Within-subject and between-subject biological variation of prothrombin time and activated partial thromboplastin time.

A genetic association study of activated partial thromboplastin time in European Americans and African Americans: the ARIC Study.

Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.

Validation of a bedside method of activated partial thromboplastin time measurement with clinical range guidelines.

Addition of prothrombin to plasma can result in a paradoxical increase in activated partial thromboplastin time.

Standardization of prothrombin and activated partial thromboplastin time reagents and controls.

Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus.

Evaluation of prothrombin time and activated partial thromboplastin time in hypertensive patients attending a tertiary hospital in calabar, Nigeria.

Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.

Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.

Importance of interdisciplinary collaboration regarding updated activated partial thromboplastin time reporting for heparin.

Influence of vitamin K antagonist treatment on activated partial thromboplastin time.

Variable response of activated partial thromboplastin time to heparin therapy during hemodialysis.

Whole-blood clotting time, activated partial thromboplastin time, and whole-blood recalcification time as heparin monitoring tests.

The effects of hemolysis on plasma prothrombin time and activated partial thromboplastin time tests using photo-optical method.

Suggest Documents

Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.

Activated partial thromboplastin time and minor coagulopathies.

An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant.

Activated partial thromboplastin time measurements in citrated canine plasma.

Sensitivity of the thrombin clotting time and activated partial thromboplastin time to low level of antithrombin III during heparin therapy.

The partial thromboplastin time.

The influence of time, temperature and packed cell on activated partial thromboplastin time and prothrombin time.

Prothrombin Time and Activated Partial Thromboplastin Time Testing: A Comparative Effectiveness Study in a Million-Patient Sample.

An analysis of duplicate testing of prothrombin time and activated partial thromboplastin time assays.

Within-subject and between-subject biological variation of prothrombin time and activated partial thromboplastin time.

A genetic association study of activated partial thromboplastin time in European Americans and African Americans: the ARIC Study.

Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.

Validation of a bedside method of activated partial thromboplastin time measurement with clinical range guidelines.

Addition of prothrombin to plasma can result in a paradoxical increase in activated partial thromboplastin time.

Standardization of prothrombin and activated partial thromboplastin time reagents and controls.

Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus.

Evaluation of prothrombin time and activated partial thromboplastin time in hypertensive patients attending a tertiary hospital in calabar, Nigeria.

Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.

Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.

Importance of interdisciplinary collaboration regarding updated activated partial thromboplastin time reporting for heparin.

Influence of vitamin K antagonist treatment on activated partial thromboplastin time.

Variable response of activated partial thromboplastin time to heparin therapy during hemodialysis.

Whole-blood clotting time, activated partial thromboplastin time, and whole-blood recalcification time as heparin monitoring tests.

The effects of hemolysis on plasma prothrombin time and activated partial thromboplastin time tests using photo-optical method.

Sensitivity and precision of activated partial thromboplastin time (APTT) methods. A multicenter study.

Recommend Documents

Follow Us